Evotec receives €6 million in milestones
This article was originally published in Scrip
Evotec has received €6 million for achieving two research milestones through its drug discovery collaboration with Boehringer Ingelheim. One milestone was for the start of lead optimisation for a specific target, while the other was for a separate programme in which Boehringer Ingelheim selected a compound for preclinical development. Boehringer Ingelheim will be responsible for the preclinical development of the identified compound, while Evotec will be entitled to additional royalties based on the compound's progress through clinical development. The two firms have been collaborating since 2004 on identifying and developing preclinical candidates for the treatment of various diseases, including CNS-related disorders, and the arrangement has been expanded and extended since its initiation. Boehringer Ingelheim has full ownership and global responsibility for developing, manufacturing and commercialising identified compounds, while Evotec receives ongoing research payments and preclinical milestones.